The US District Court for the Southern District of Florida has ruled that Watson Pharmaceuticals' generic versions of Mucinex, Mucinex D and Mucinex DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and seudoephedrine/Guaifenesin) Extended-Release drugs do not infringe US Patent No 6,372,252.
The Mucinex products are indicated to loosen mucus and thin bronchial secretions to clear the bronchial passageways of troublesome mucus and make coughs more productive.
In 2009, Reckitt Benckiser filed a suit against Watson for patent infringement related to the generic versions of Mucinex.
No comments:
Post a Comment